OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Tarhini on the Combination of High-Dose Bolus IL-2 and CTLA-4 Inhibition in Advanced Melanoma

August 19th 2024

Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in RCC

August 19th 2024

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.

Dr Leidner on the DPV-001 Vaccine Plus PD-1 Inhibition in Metastatic HNSCC

August 19th 2024

Rom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.

Dr Watts on the Final Results of the 2102-HEM-101 Trial in IDH1-Mutated AML

August 16th 2024

Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.

Dr Tarhini on Hogh-Dose Bolus IL-2 With Ipilimumab Followed by Nivolumab in Melanoma

August 16th 2024

Ahmad Tarhini, MD, PhD, discusses the use of high-dose bolus IL-2 with ipilimumab followed by nivolumab in advanced melanoma following prior progression.

Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI Combos

August 16th 2024

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

Dr Piulats on Validating Predictive Biomarkers for Talazoparib Plus Enzalutamide in mCRPC

August 16th 2024

Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.

Dr Banerjee on Selecting Between Bispecific and CAR T-Cell Treatments in Myeloma

August 16th 2024

Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma

Dr Braun on the Current Kidney Cancer Treatment Paradigm

August 16th 2024

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.

Dr Kim on Current Unmet Needs in the Management of Resectable CRC

August 16th 2024

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies

August 16th 2024

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Dr Stiles on the FDA Approval of Perioperative Durvalumab Plus Chemo in NSCLC

August 15th 2024

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

Dr Christenson on the Safety of Copanlisib Plus Nivolumab in Pretreated MSS mCRC

August 15th 2024

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

Dr Hursting on Weight Loss Drugs and the Potential to Reduce Obesity-Related Breast Cancer

August 15th 2024

Dr Randall on the Role of EZH2 in Doxorubicin Resistance in Soft Tissue Sarcoma

August 15th 2024

R. Lor Randall, MD, FACS, discusses the role of EZH2 in doxorubicin resistance in soft tissue sarcoma.

Dr Kalinsky on Unmet Needs and Findings from RxPONDER in HR+/HER2– Breast Cancer

August 15th 2024

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

Dr Adam on Efforts to Reduce Recurrence Risk in CRC Liver Metastases

August 15th 2024

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

August 15th 2024

Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.

Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver Metastases

August 15th 2024

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLC

August 15th 2024

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.